Simple, Inexpensive Genetic Test Can Identify MS Patients at Risk of Fatal Brain Infection
By LabMedica International staff writers Posted on 20 Mar 2023 |
Patients with multiple sclerosis (MS) are confronted with a difficult decision - whether they should take medications that have proven to be effective in slowing the disease's progression, despite the potential risk of triggering a fatal brain infection called progressive multifocal leukoencephalopathy (PML). This rare complication occurs when the JC virus, which is prevalent but usually dormant in most carriers, becomes active. Immune-modifying medications, including those prescribed for MS treatment, have been linked to PML in rare cases. As more potent immunosuppressive drugs become available, drug-induced PML is becoming increasingly common.
Now, leading MS experts are recommending genetic testing to identify MS patients with an increased likelihood of experiencing serious medication side effects. Joseph Berger, MD, MS Division Chief at the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA, USA), and Hans-Peter Hartung, MD, Neurology Chair of Heinrich Heine University (Düsseldorf, Germany), have come out in support of a new study that confirms a strong link between four genetic mutations and PML. These mutations were found to be significantly more common in MS patients who took PML-linked drugs and later developed PML compared to those who took similar medications but did not develop PML.
"The availability of a simple, relatively inexpensive test that can identify the genes that put one at risk for PML would be enormously helpful in the management of patients. The widespread use of such testing could potentially allow the physician to use alternative therapies that do not carry the same risk of PML," stated Drs. Berger and Hartung.
Related Links:
University of Pennsylvania Perelman School of Medicine
Heinrich Heine University
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection